Ovarian cancer treatment is much more effective if it’s administered during the early stages of the disease. In fact, when ovarian cancer is diagnosed early, approximately 94% of patients have a good prognosis post-treatment.
However, the reality is that relatively few cases (about 20%) of ovarian cancer are diagnosed early, which makes treatment less effective. But a newly developed blood test could change this.
Beyong a full pelvic exam, medical professionals, at present, have two options when it comes to testing for ovarian cancer: a transvaginal ultrasound and a cancer antigen 125 (CA 125) blood test.
Unfortunately, both have significant limitations. For example, while the ultrasound can detect growths, it cannot determine whether they are cancerous. The CA 125 test looks for a specific ovarian cancer marker, but people with unrelated conditions also have high levels of this particular antigen.
These limitations of the existing tests are one of the driving forces behind the development of the new blood test.
The new test, developed by a team from Griffith University and the University of Adelaide (both in Australia), looks for telltale sugars associated with ovarian cancer cells.
According to the findings of the team’s study, the new blood test detected large levels of the sugars in 90% of people with stage 1 ovarian cancer and 100% of people with later stage ovarian cancer.
Moreover, the test detected none of the telltale sugars in healthy participants.
Prof. James Paton, one of the study authors, said the test is a huge step toward diagnosing ovarian cancer in its early stages.
“Ovarian cancer is notoriously difficult to detect in its early stages, when there are more options for treatment and survival rates are better. Our new test is therefore a potential game-changer,” he said.